About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: KPTI
- Previous Close: $10.58
- 50 Day Moving Average: $10.44
- 200 Day Moving Average: $9.23
- 52-Week Range: $5.50 - $11.41
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.81
- P/E Growth: 0.27
- Market Cap: $430.99M
- Outstanding Shares: 41,243,000
- Beta: 4.49
- Return on Equity: -64.20%
- Return on Assets: -58.62%
Companies Related to Karyopharm Therapeutics:
- Current Ratio: 8.71%
- Quick Ratio: 8.71%
What is Karyopharm Therapeutics' stock symbol?
Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."
Where is Karyopharm Therapeutics' stock going? Where will Karyopharm Therapeutics' stock price be in 2017?
10 equities research analysts have issued 1-year price objectives for Karyopharm Therapeutics' stock. Their forecasts range from $7.55 to $28.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $16.05 in the next twelve months.
When will Karyopharm Therapeutics announce their earnings?
Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
What are analysts saying about Karyopharm Therapeutics stock?
Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:
According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (12/7/2016)
Jefferies Group LLC analysts commented, "We believe evolving efficacy/safety data, coupled with mgmt's expertise in the disease area and the continuing unmet need, increases the likelihood (our POS increases to 55 percent from 30 percent) Selinexor will ultimately reach the mkt and generate MM sales of >$500 million by 2025," analyst Brian Abrahams wrote in a note.Near- And Long-Term PositivesMeanwhile, Selinexor is currently in 35 studies exploring multiple tumor types, increasing the potential to optimize indication, dosing and combination. Based on preclinical results, Abrahams believes that data from next-gen XPO1 inhibitor '8602 later this year offer another means to exploit the potential of that agent to target the mechanism with fewer side effects with lower side effects. In addition, the PAK4/NAMPT inhibitor '9274 could potentially broaden the company's long-term opportunity."Though Selinexor's narrow therapeutic window remains the biggest limitation, recent studies (e.g., STOMP) at more optimized doses appear based on our analysis to suggest more acceptable AEs," (8/30/2016)
Who owns Karyopharm Therapeutics stock?
Karyopharm Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (11.47%), Franklin Resources Inc. (7.83%), Palo Alto Investors LLC (7.76%), State Street Corp (0.98%), Dimensional Fund Advisors LP (0.63%) and TCW Group Inc. (0.10%). Company insiders that own Karyopharm Therapeutics stock include Barry E Greene, Justin A Renz, Ltd Chione, Mansoor Raza Mirza and Ran Frenkel.
Who sold Karyopharm Therapeutics stock? Who is selling Karyopharm Therapeutics stock?
Karyopharm Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc. and Tudor Investment Corp Et Al. Company insiders that have sold Karyopharm Therapeutics stock in the last year include Ltd Chione and Ran Frenkel.
Who bought Karyopharm Therapeutics stock? Who is buying Karyopharm Therapeutics stock?
Karyopharm Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Palo Alto Investors LLC, Russell Investments Group Ltd., Trexquant Investment LP, State Street Corp and Metropolitan Life Insurance Co. NY. Company insiders that have bought Karyopharm Therapeutics stock in the last two years include Barry E Greene, Justin A Renz and Ran Frenkel.
How do I buy Karyopharm Therapeutics stock?
Shares of Karyopharm Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Karyopharm Therapeutics stock cost?
One share of Karyopharm Therapeutics stock can currently be purchased for approximately $10.58.